Jonathan Slonin - Dec 6, 2023 Form 3 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Medical Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Dec 6, 2023
Transactions value $
$0
Form type
3
Date filed
12/7/2023, 07:44 PM
Previous filing
Jun 7, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCRX Common Stock 45.9K Dec 6, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PCRX Stock Option (Right to Buy) Dec 6, 2023 Common Stock 27.5K $38.74 Direct F2
holding PCRX Stock Option (Right to Buy) Dec 6, 2023 Common Stock 24.8K $59.39 Direct F2
holding PCRX Stock Option (Right to Buy) Dec 6, 2023 Common Stock 10K $60.79 Direct F2
holding PCRX Stock Option (Right to Buy) Dec 6, 2023 Common Stock 14.1K $60.96 Direct F2
holding PCRX Stock Option (Right to Buy) Dec 6, 2023 Common Stock 35.5K $52.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 27,452 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 10,950 restricted stock units that vest in four equal annual installments on June 3, 2024, June 3, 2025, June 3, 2025 and June 3, 2026; (ii) 7,425 restricted stock units that vest in three equal annual installments on June 3, 2024, June 3, 2025 and June 3, 2026; (iii) 2,500 restricted stock units that vest in two equal annual installments on August 1, 2024 and August 1, 2025; (iv) 2,827 restricted stock units that vest in two equal annual installments on June 3, 2024 and June 3, 2025; and (v) 3,750 restricted stock units that vest on July 1, 2024; in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

Although the reporting person was previously deemed to be an "officer" of the issuer for purposes of Section 16, the issuer's board of directors (the "board") determined, at a meeting held on June 14, 2023, that the reporting person should no longer be designated a Section 16 "officer." However, in connection with his expected performance of certain significant policy-making functions for the issuer as a result of his promotion to Chief Medical Officer on December 5, 2023, the board determined, at a meeting held on December 6, 2023, that the reporting person should once again be designated a Section 16 "officer" of the issuer. As a result, the reporting person is filing this Initial Statement of Beneficial Ownership of Securities on Form 3.